Towards the development of next-generation MergoTM — a nucleic acid-based delivery platform
Towards the development of next-generation MergoTM — a nucleic acid-based delivery platform
Nucleic acids offer great potential for therapeutic and drug delivery applications, but their clinical translation is hindered by several biological barriers. This thesis addresses some of these challenges by optimising Sixfold's Mergo system, a self-assembled RNA construct, for the in vivo delivery of siRNAs. Focusing on stability, cellular uptake, endosomal escape, and off-target effects, we performed a comprehensive investigation of Mergo's performance in different biological matrices.
To ensure efficient delivery of intact therapeutics, stabilising Mergo systems against nucleolytic degradation is essential. Through detailed analysis of Mergo and other RNA constructs in biological matrices, we identified vulnerable regions and implemented strategies to enhance nuclease resistance. These strategies included specific chemical modifications and the design of novel linkers engineered for controlled siRNA release at the target site.
Further investigation focused on the critical steps of cellular uptake and endosomal escape, which are known bottlenecks for nucleic acid-based therapies. While cellular uptake of Mergo was readily achieved, endosomal escape was identified as the rate-limiting steps for Mergo in vitro.
Finally, to assess the safety and efficacy of Mergo, we employed a combination of in silico, in vitro, and in vivo studies to evaluate both on- and off-target effects. This work not only provided preliminary insights into Mergo's potential for therapeutic delivery but also established a valuable methodology for evaluating future RNA-based delivery systems and therapeutics.
In summary, this thesis investigates the challenges and opportunities of the Mergo delivery system. By addressing key barriers, this work aims to accelerate the development of Mergo as a promising delivery platform for clinical applications. Furthermore, as Mergo is RNA-based, this research contributes to a broader understanding of the challenges and opportunities within the RNA delivery and therapeutics field.
University of Southampton
Reyes Fraile, Laura
28382e18-236f-427f-ae88-32ae7e38f3b3
2026
Reyes Fraile, Laura
28382e18-236f-427f-ae88-32ae7e38f3b3
Stulz, Eugen
9a6c04cf-32ca-442b-9281-bbf3d23c622d
Thompson, Sam
99b7e34e-fe24-401c-b7b0-64e56cbbbcb1
Reyes Fraile, Laura
(2026)
Towards the development of next-generation MergoTM — a nucleic acid-based delivery platform.
University of Southampton, Doctoral Thesis, 282pp.
Record type:
Thesis
(Doctoral)
Abstract
Nucleic acids offer great potential for therapeutic and drug delivery applications, but their clinical translation is hindered by several biological barriers. This thesis addresses some of these challenges by optimising Sixfold's Mergo system, a self-assembled RNA construct, for the in vivo delivery of siRNAs. Focusing on stability, cellular uptake, endosomal escape, and off-target effects, we performed a comprehensive investigation of Mergo's performance in different biological matrices.
To ensure efficient delivery of intact therapeutics, stabilising Mergo systems against nucleolytic degradation is essential. Through detailed analysis of Mergo and other RNA constructs in biological matrices, we identified vulnerable regions and implemented strategies to enhance nuclease resistance. These strategies included specific chemical modifications and the design of novel linkers engineered for controlled siRNA release at the target site.
Further investigation focused on the critical steps of cellular uptake and endosomal escape, which are known bottlenecks for nucleic acid-based therapies. While cellular uptake of Mergo was readily achieved, endosomal escape was identified as the rate-limiting steps for Mergo in vitro.
Finally, to assess the safety and efficacy of Mergo, we employed a combination of in silico, in vitro, and in vivo studies to evaluate both on- and off-target effects. This work not only provided preliminary insights into Mergo's potential for therapeutic delivery but also established a valuable methodology for evaluating future RNA-based delivery systems and therapeutics.
In summary, this thesis investigates the challenges and opportunities of the Mergo delivery system. By addressing key barriers, this work aims to accelerate the development of Mergo as a promising delivery platform for clinical applications. Furthermore, as Mergo is RNA-based, this research contributes to a broader understanding of the challenges and opportunities within the RNA delivery and therapeutics field.
Text
PhD_Thesis_LauraReyes_2
- Version of Record
Restricted to Repository staff only until 9 November 2028.
Text
Final-thesis-submission-Examination-Miss-Laura-Reyes-Fraile
Restricted to Repository staff only
More information
Submitted date: November 2025
Published date: 2026
Identifiers
Local EPrints ID: 508356
URI: http://eprints.soton.ac.uk/id/eprint/508356
PURE UUID: 276c1a5f-c0dd-4009-b4fe-da5c866867ea
Catalogue record
Date deposited: 19 Jan 2026 18:04
Last modified: 20 Jan 2026 02:49
Export record
Contributors
Author:
Laura Reyes Fraile
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics